Patience Plus Persistence Equals Progress!
Occasionally it’s nice to sit back and take stock of all that your association has accomplished in the recent past—and all that still needs to be worked on. Our founder Jon Terry describes what your association has been working on since 2011 but be assured we do not plan to rest on our laurels. We plan to expand our education and funding efforts with the Epi Near You New York program, and continue our work to support lower priced epinephrine auto-injectors. You can read the full article here.
Patience + Persistence = Progress!
Update on Our Latest Accomplishments and Plans for the Future
By Jon Terry
August 8th, 2018
As the summer moves quickly towards fall, September 23rd is fast approaching. On that day it will be nine years since my sister Ruth T. Cornell died from a fatal attack of anaphylaxis after being stung by a honey bee. Keeping that in mind, this seems like a good time to share with all our affiliates and supporters some ideas of where our association is headed. To do that I would like to list a few milestones we have already passed in 2018.
- New York State approval of Epi Near You New York training program
- Epi Entity Stocking Gift provided to Saint John Fisher College
- USAnaphylaxis Summit Meeting in Nashville
- Epi Entity Stocking Gift provided to Seneca Waters Council Boy Scouts of America
- Food Allergy Awareness Day at the State Capitol in Albany
- Epi Entity Stocking Gift provided to Girl Scouts of America Western NY
- Pharmacists Society of the State of NY convention in Buffalo
- Educational Gift awarded to U-R Condemi Rosenfeld Scholarship Fund
- Educational Gift awarded FARE Hero's Walk in Buffalo
- Food Allergy Awareness Day at Frontier Field in Rochester
Since our association was founded in 2011, we have accomplished a lot. Our public outreach efforts include a Web site acting as a clearing house of allergy and asthma information, a free monthly e-newsletter, exhibiting at health fairs and community events across western NY, presentations to numerous audiences providing anaphylaxis emergency response training, advocacy for laws protecting individuals with life-threatening allergies and improving public access to life-saving epinephrine, gifts and grants to 501c3 non-profit organizations engaged in education and research. And as we move forward we intend to accomplish a lot more.
EPI NEAR YOU NEW YORK is our most ambitious project to date. ENYNY is an educational program to help Monroe County’s small businesses keep their customers safe from life-threatening allergies. This program will enable businesses to stock and administer epinephrine to those who are not carrying their epinephrine auto-injector (EAI) device or weren’t aware of their allergy, leaving them at risk for an attack of anaphylaxis.
Our training program is available to businesses which serve the public, offering food or providing exposure to other possible allergens. These businesses include a wide range of categories such as restaurants, summer camps, and daycare centers. After taking our NYS approved training program, businesses will receive a certificate and a non-patient-specific (NPS) prescription, which can be filled at any pharmacy in NYS. Additionally, the Allergy Advocacy Association will provide a payment voucher for 501c3 organizations.
Another project our association fully supports is improving access to epinephrine to all consumers at the lowest possible price. At a time when the costs of almost all medications continue to increase year after year, we believe that GENERIC DRUGS offer patients the ways and means to reduce their health care costs effectively. We also believe that generic versions of the epinephrine auto-injector device are essential to protecting and saving lives from anaphylaxis.
According to the US Food and Drug Administration, a generic drug is a medication created to be the same as an existing approved brand-name drug in dosage form, safety, strength, route of administration, quality, and performance characteristics.
Generic medicines tend to cost less than their brand-name counterparts because they do not have to repeat animal and clinical (human) studies that were required of the brand-name medicines to demonstrate safety and effectiveness. In addition, multiple applications for generic drugs are often approved to market a single product; this creates competition in the marketplace, typically resulting in lower prices.
The reduction in upfront research costs means that, although generic medicines have the same therapeutic effect as their branded counterparts, they are typically sold at substantially lower costs. When multiple generic companies market a single approved product, market competition typically results in prices about 85% less than the brand-name. According to the IMS Health Institute, generic drugs saved the U.S. health care system $1.67 trillion from 2007 to 2016.
The Allergy Advocacy Association fully supports all efforts to improve access to generic versions of epinephrine. In New York State we have advocated diligently to encourage sales of generic epinephrine auto-injector devices by introducing new legislation clarifying existing generic legislation. And we have actively publicized new generic devices when they finally become available. Regardless of the ailment or the prescribed medication, generic drugs encourage competition throughout the pharmaceutical industry thereby lowering the cost to consumers.
To increase the effectiveness of our program of AWARENESS, ALERTNESS and ACTION, our association needs your support. The more individuals, organizations and corporations that donate their time, talents and money, the more lives we can protect and save. The goal of the Allergy Advocacy Association is a clear and direct one. "Not another life lost to anaphylaxis. Not another life lost to ANY life-threatening allergies!"
© Copyright Allergy Advocacy Association 2018.